PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY
Nicoletta Colombo(European Institute of Oncology), Emese Zsíros(Roswell Park Comprehensive Cancer Center), Alexandra Sebastianelli(Université Laval), Mariusz Bidziński(Polish Geological Institute), Carlos Gallardo, Emad Matanes(Rambam Health Care Campus), Kosei Hasegawa(Saitama Medical University), Fatih Köse(Başkent University), Manuel Magallanes(MSD (Mexico)), Rebecca Herbertson(University Hospitals Sussex NHS Foundation Trust), Jeffrey C. Goh(Gallipoli Medical Research Foundation), Judith R. Kroep(Leiden University Medical Center), Andréia Cristina de Melo(Instituto Nacional do Câncer), Philip R. Debruyne(AZ Groeninge), Jae‐Weon Kim(Seoul National University), Xuan Peng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karin Yamada(Merck & Co., Inc., Rahway, NJ, USA (United States)), Agata M. Bogusz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thibault De La Motte Rouge(Centre Eugène Marquis), Xiaohua Wu(Fudan University Shanghai Cancer Center)
Cited by 2
Abstract
Related Papers
No related papers found
Powered by citation graph analysis